Inclusion Criteria:

- Age 18 or older

- Willing to provide informed consent

- ECOG performance status 0-2

- Histologically confirmed non-small cell lung carcinoma

- Locally advanced stage IIIA or IIIB lung carcinoma according to AJCC 7th edition

- Expected lung V20 of 35-60%, as determined at the time of 4D-CT simulation

- Assessment by medical oncologist and radiation oncologist, with adequate hepatic and
renal function for administration of cisplatin-based doublet chemotherapy, at the
discretion of the medical oncologist

Exclusion Criteria:

- Serious medical comorbidities or other contraindications to radiotherapy or
chemotherapy

- Prior history of lung cancer within 5 years

- Prior thoracic radiation at any time

- Metastatic disease

- in some select cases, patients with a solitary metastasis (i.e. brain metastasis) may
receive radical chemoradiotherapy after resection/ablation of their metastatic
lesion, as standard practice. In such cases, the patient may be enrolled onto this
study at the discretion of the local principle investigator once the metastasis has
been treated.

- inability to attend full course of radiotherapy of follow-up visits

- Pregnant or lactating women